Implantica's RefluxStop® Debuts in U.S. with Strong Surgeon…

Event summary

Implantica's RefluxStop® received FDA Premarket Approval (PMA) and launched in the U.S. at the 2026 American Foregut Society Meeting.
The launch event drew over 120 surgeons and gastroenterologists, with the panel moderated by AFS past President Dr. John Lipham.
RefluxStop® offers a non-encircling approach to treating GERD, addressing a market of 78 million Americans.
The procedure aims to restore natural anatomy and physiology, minimizing post-surgical side effects like swallowing difficulties.
Implantica reported nearly 30 one-on-one meetings with top surgeons and GIs interested in introducing RefluxStop® at their institutions.

The big picture

Implantica's U.S. launch of RefluxStop® marks a strategic inflection point in the GERD treatment landscape. With over 40% of U.S. patients experiencing symptoms despite daily medication, the non-encircling approach of RefluxStop® addresses a significant unmet need. The strong reception at the American Foregut Society Meeting suggests potential for rapid adoption, but the company's ability to scale and maintain clinical outcomes will be critical to long-term success.

What we're watching

Adoption Pace: The pace at which leading U.S. medical institutions will integrate RefluxStop® into clinical practice.
Market Penetration: Whether Implantica can sustain the initial enthusiasm and convert it into significant market share.
Competitive Response: How traditional anti-reflux treatment providers will react to RefluxStop®'s disruptive approach.